Cargando…
HGG-37. UPFRONT TARGETED THERAPY FOR THE TREATMENT OF BRAFV600E-MUTANT PEDIATRIC HIGH-GRADE GLIOMA – A MULTI-INSTITUTIONAL EXPERIENCE
INTRODUCTION: Sustained responses to molecular targeted therapy with BRAF with or without MEK inhibitors have been reported in patients with recurrent BRAFV600E-mutant pediatric high-grade gliomas (pHGG). The role of upfront targeted therapy in this population, however, has not yet been established....
Autores principales: | Rosenberg, Tom, Yeo, Kee Kiat, Joshirao, Mrinal, Michaiel, George, Tran, Hung, Dahiya, Sonika, Kachurak, Kara, Friedman, Gregory, Huang, Michael, Wright, Karen, Aguilera, Dolly, MacDonald, Tobey, Chi, Susan, Karajannis, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168236/ http://dx.doi.org/10.1093/neuonc/noab090.101 |
Ejemplares similares
-
HGG-47. DECREASED GROWTH VELOCITY WITH LONG TERM USE OF BRAFV600e AND MEK INHIBITION IN A PATIENT WITH ANAPLASTIC GANGLIOGLIOMA
por: Tran, Hung, et al.
Publicado: (2020) -
HGG-35. Radiation Induced High Grade Gliomas: A Single Center Experience
por: Joshirao, Mrinal, et al.
Publicado: (2022) -
HGG-02. ADOLESCENT AND YOUNG ADULT (AYA) GLIOMA WITH BRAF V600E-MUTANTATION
por: Kimura, Yui, et al.
Publicado: (2020) -
HGG-39. Integrative analyses of BRAFp.v600e mutated gliomas: from epigenetic to metabolic characteristics
por: Lhermitte, Benoit, et al.
Publicado: (2022) -
HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)